Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., said it completed its public offering of 240,000 shares of series B convertible preferred stock and warrants to purchase 24 million shares of common stock at $25. One share of series B convertible preferred stock is combined with 100 warrants to purchase one share of common stock each with an exercise price of $0.275 per share.